1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

M Burotto,L.A Herraez Baranda,E Felip,S Kshirsagar,E Pozzi,Z Zvirbule,V Maiya,E Restuccia,P Chanu

doi:10.1016/j.annonc.2020.08.1584

1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

M Burotto, L.A Herraez Baranda + Show 7 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.1584

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
License type: publisher-specific-oa

Affiliation: Vall d'Hebron Hospital Universitari, Roche (Switzerland), Latvian Biomedical Research and Study Centre, La Roche College, Roche (France)

#Metastatic Non-small Cell Lung Cancer #Atezolizumab In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Full Text